Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

PHASE4CompletedINTERVENTIONAL
Enrollment

278

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

April 24, 2022

Study Completion Date

April 24, 2022

Conditions
Treatment Resistant Major Depressive Disorder
Interventions
DRUG

Aripiprazole

Oral adjunctive therapy with aripiprazole, dose adjusted for effectiveness and tolerability.

DEVICE

Repetitive transcranial magnetic stimulation (rTMS)

Adjunctive therapy with transcranial magnetic stimulation, dose adjusted for effectiveness and tolerability.

DRUG

Venlafaxine XR

Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.

Trial Locations (13)

10003

New York University, New York

19104

University of Pennsylvania, Philadelphia

29425

Roper St. Francis Hospital, Charleston

33613

University of South Florida, Tampa

35294

The University of Alabama School of Medicine, Birmingham

45219

University of Cincinnati, Cincinnati

60611

Northwestern University, Feinberg School of Medicine, Chicago

75390

University of Texas Southwestern Medical Center, Dallas

77030

Baylor College of Medicine, Houston

90095

Pacific Institute of Medical Research, Los Angeles

94305

Stanford University, Stanford

Unknown

University of British Columbia, Vancouver

R2H 2A6

University of Manitoba St. Boniface Hospital, Winnipeg

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

lead

Massachusetts General Hospital

OTHER

NCT02977299 - Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD | Biotech Hunter | Biotech Hunter